TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03354767

Intervention type: PROCEDURE
Intervention: Aortic and aortic valve surgery

Intervention type: PROCEDURE
Intervention: Aortic and aortic valve surgery
Study: NCT02944708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy 2
Study: NCT03367403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donanemab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donanemab
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202626
Description: Administered orally
Study: NCT00194077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: dosing will occur at 2mg, 5mg, 7mg, 10 mg, 12mg, or 15 mg based on weight, side effects and efficacy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subjects in phase 2 will be randomized to active abilify or placebo
Study: NCT02509468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: * each patient will be followed during a 12-month-period~* each patient will start by an observational period and end being treated by sirolimus~* at a random date (between month 4 and month 8), each patient will switch from the observational period to the sirolimus period
Study: NCT03444103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clazakizumab / Clazakizumab
Description: Humanized monoclonal anti-IL-6 antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo / Clazakizumab
Description: 0.9% Saline
Study: NCT00272831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: Cilostazol 100 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet twice daily
Study: NCT02008942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL2200 Aspirin Capsules
Description: 325 mg aspirin; once per day for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric-coated aspirin caplets
Description: 325 mg aspirin; once per day for 10 days
Study: NCT03633994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Heparin is a readily available glycosaminoglycan (GAG) chemically similar to hyaluronic acid and chondroitin sulfate that is currently used to treat chronic painful bladder or interstitial cystitis. Heparin intravesical treatment is an inexpensive second-line treatment for chronic painful bladder, characterized by urinary frequency, urgency and pain. Heparin has been shown to re-establish the bladder urothelial GAG layer and as already noted was shown to reduce recurrent urinary tract infections by 50%.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline bladder instillation
Study: NCT01005199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Sorafenib 2 x 400 mg daily plus everolimus 1 x 5 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Sorafenib 2 x 400 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Sorafenib 2 x 400 mg daily
Study: NCT01335191

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two subcutaneous injections of Placebo at Day 0 and Week 3.
Study: NCT00822783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00920283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chrono Carbostent Carbofilm™ Coated Coronary Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Driver Cobalt Alloy Coronary Stent
Study: NCT00971594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary counseling
Description: 1 hour sessions, once per week, with a registered dietitian on the American Heart Association Step I diet with caloric intake for each volunteer adjusted by the dietitian to elicit a WL of \~0.2-0.4 kg/wk

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AEX
Description: Moderate aerobic exercise (75-80% HRR for 45 min) at the Baltimore GRECC exercise facility using treadmills 3 times per week for 6 months.
Study: NCT02646072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac tromethamine ophthalmic solution 0.45%
Description: Indicated for the treatment of pain and inflammation following cataract surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac tromethamine ophthalmic solution 0.45%
Description: Indicated for the treatment of pain and inflammation following cataract surgery.
Study: NCT01452724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 20 mg, tablets, orally, once daily for up to 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lansoprazole placebo-matching capsules, orally, once daily for up to 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 30 mg, capsules, orally, once daily for up to 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: TAK-438 placebo-matching tablets, orally, once daily for up to 6 weeks.
Study: NCT03607071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone and taper
Description: Prednisolone 30 mg/d and taper 5-10 mg per 2 weeks until off at week 24.
Study: NCT02281968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Standing regimen of naproxen in experimental group to reduce need for narcotic to control pain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03685110

Intervention type: DEVICE
Intervention: CoreHip Total Hip Arthroplasty
Description: Replacement of the Hip Joint
Study: NCT05467488

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: photofunctionalization
Description: UVA and UVC photofunctionalization of dental implants

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: photofunctionalization
Description: UVA and UVC photofunctionalization of dental implants
Study: NCT01498588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Patients will receive 4 cycles of neoadjuvant eribulin followed by 4 cycles of dose-dense doxorubicin and cyclophosphamide (AC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
Study: NCT06790615

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methyl prednisolone acetate
Description: methyl prednisolone acetate was injected after the aspiration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silk suture
Description: The silk suture was used for threading technique
Study: NCT01498588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Growth factor support (pegfilgrastim) can be given at the discretion of the investigator. Administration of pegfilgrastim is required 24 to 48 hours following administration of dose-dense doxorubicin and cyclophosphamide.
Study: NCT06792383

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: quality of life
Description: The following assessment tools will be proposed to patients:~* Quality of Life in Epilepsy (QOLIE-31)26~* Dissociative Experience Scale (DES)27~* Symptom Checklist-90 (SCL-90)28~* Irritability Questionnaire (I-EPI)29~* Beck Depression Inventory II (BDI-II)30~* State-Trait Anxiety Inventory Y-1 e Y-2 (STAI)31~* Epilepsy Stigma Scale modificata32 These assessment tools are validated and used universally, and will allow the collection of information on the psychological and psychiatric functioning of the patients.
Study: NCT02919410

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iodophor-impregnated adhesive drapes

Intervention type: OTHER
Group type: OTHER
Intervention: No adhesive drapes
Study: NCT06791746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: compound Staphylococcal lysostaphin mouthrinse
Description: Lysostaphin is a proteolytic enzyme produced by a specific species of Staphylococcus, uniquely capable of cleaving the cross-linking pentaglycine bridges within the cell walls of Staphylococcus aureus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine mouthrinse
Description: Chlorhexidine mouthrinse offers a cost-effective prophylactic approach to preventing OM.
Study: NCT03168841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efinaconazole Topical
Description: Enrolled subjects will be dispensed medical for topical application, and followed for a period of 50 weeks.
Study: NCT04238689

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TB31F
Description: Monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TB31F
Description: Monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TB31F
Description: Monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TB31F
Description: Monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TB31F
Description: Monoclonal antibody
Study: NCT01437267

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-CRM197 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-CRM197 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-CRM197 vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vi Polysaccharide (PS) vaccine
Study: NCT02434653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring hemoglobin levels following anemia associated symptoms
Description: Post-partum anemia will be diagnosed after vaginal delivery by taking hemoglobin levels to patients with symptoms consistent with anemia, severe postpartum hemorrhage or hemoglobin level below 8 g/dL.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring hemoglobin levels to detect anemia by screening of women at increased risk for post partum anemia
Description: Post-partum anemia will be diagnosed after vaginal delivery by taking hemoglobin levels to high risk women for post-partum anemia, defined as hemoglobin levels of 10.5 g/dl or below around delivery, or severe postpartum hemorrhage with or without symptoms associated with anemia
Study: NCT03364491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: A single dose of Tranexamic Acid (1 gram) in normal saline for a total of 50cc, administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 cc normal saline administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)
Study: NCT03770780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-718
Description: SAGE-718 in combination with Ketamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in combination with Ketamine
Study: NCT02140606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cafusertib Hydrochloride
Description: Drug: Cafusertib Hydrochloride (d1 and 15) Cafusertib (d1 and 15 - one hour iv.v) Drug: Cytarabine Cytarabine 2 x 20 mg/d s.c. d1-15.
Study: NCT03415581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Oxycodone
Description: Under each doxazosin maintenance condition the effects of intranasal oxycodone will be assessed in order to determine if doxazosin reduces dependent measures assessing its abuse potential.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Oxycodone
Description: Under each doxazosin maintenance condition the effects of intranasal oxycodone will be assessed in order to determine if doxazosin reduces dependent measures assessing its abuse potential.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cue Session
Description: During the cue exposure session participants are presented with neutral cues followed by drug-related cues. This procedure will allow the investigators to determine whether the study medication affects reactivity to drug-related cues.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cue Session
Description: During the cue exposure session participants are presented with neutral cues followed by drug-related cues. This procedure will allow the investigators to determine whether the study medication affects reactivity to drug-related cues.
Study: NCT01696799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Econazole Nitrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Econazole Nitrate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02350075

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental implants installation
Description: Dental implants installation is a procedure to insert dental implants into alveolar bone.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dental implants installation
Description: Dental implants installation is a procedure to insert dental implants into alveolar bone.

Intervention type: DEVICE
Group type: OTHER
Intervention: Osteotome Sinus floor elevation
Description: Osteotomes with different diameters are specially-designed device to vertically increase the bone volume in atrophic maxilla.
Study: NCT02317601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone sodium succinate
Description: Single dose Intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo saline
Study: NCT04566952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib will be treated with its minimum dose that is orally 8 mg daily on days 1-14 of a 21-days cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be treated with a total daily dose of 450 or 300mg.
Study: NCT04242576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Right Left Judgement
Description: It is an application by Noigroup (Neuro Orthopedic Institute), adapted to different devices.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation
Description: Videos of cervical movements.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Evidence based exercises for the neck.
Study: NCT00820807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel dietary fiber
Description: oral consumption in beverage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel dietary fiber
Description: oral consumption in beverage

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral consumption in beverage
Study: NCT01489267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: The patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments and the dose is about 2 ml(including 1×10'7 cells).
Study: NCT01665872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Group Therapy
Description: CBT Group

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Group Therapy
Description: CBT Group
Study: NCT02143960

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VelaShape III
Description: Subjects will receive one treatment to their entire waist / love-handle/ flanks area in a split-waist fashion, so that one side is treated with one device and the other side is treated with the other device. The treatment session will include: one side (right or left) treated with the VelaShape III device and the other side (left or right, respectively) with the CoolSculpt device. The subject will be randomized to one of 2 treatment groups, one will receive treatment to the left side with the VelaShape II and the right side will receive treatment with the CoolSculpt. The other group will receive treatment to right side with the VelaShape II and the left side will receive treatment with the CoolSculpt.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CoolSculpt
Description: Noninvasive Cryolipolysis
Study: NCT03672357

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic liver resection
Description: Laparoscopic hepatectomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open liver resection
Description: Traditional open hepatectomy
Study: NCT04199546

Intervention type: OTHER
Group type: OTHER
Intervention: Chewing and swallowing rehabilitation
Description: A home based chewing and swallowing training program (CST) will be applied by an experienced physical therapist. The Functional Chewing Training will be used to improve chewing function which has five steps including positioning the child and food, sensory stimulation, chewing training and adjustment of food consistency to improve chewing function. To support hyolaryngeal elevation, laryngeal mobilization will be performed. Hyolaryngeal mobilization will be performed by moving hyolaryngeal complex in right, left and up directions manually.
Study: NCT02108834

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nerve block
Description: After general anaesthesia,the patient is placed in a supine position with the head turn away from the side to be blocked, and then the sternocleidomastoid muscle (SCM) is identified by slight head elevation. SCPB(superficial cervical plexus block) is performed with a 26-gauge needle that is inserted at the midpoint of the posterior border of the SCM muscle and the needle is advanced just past the SCM muscle. The mixture is prepared with 20ml of 0.5% ropivacaine in Group 1

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: After general anaesthesia,the patient is placed in a supine position with the head turn away from the side to be blocked, and then the sternocleidomastoid muscle (SCM) is identified by slight head elevation. SCPB(superficial cervical plexus block) is performed with a 26-gauge needle that is inserted at the midpoint of the posterior border of the SCM muscle and the needle is advanced just past the SCM muscle. The mixture is prepared with 20ml of 0.9% saline in Group 2.
Study: NCT04331925

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Anxiety and depression screening
Description: At the time of consent, the participant parent will be randomized into either the control or intervention groups. The control group will complete the Hospital Anxiety and Depression Scale (HADS) questionnaire at the start of the study. After two weeks or at the time of discharge, the control group will complete the HADS questionnaire again.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Journaling
Description: Parents randomized into the intervention group be given verbal instructions to use a journal how/when they choose for the duration of the intervention period

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Journaling
Description: Parents randomized into the intervention group be given verbal instructions to use a journal how/when they choose for the duration of the intervention period
Study: NCT04071171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVVH with Phoxilium® in the first 48h after randomization
Description: After randomization into the Phoxilium®-group, CVVH will be initiated with Phoxilium® as a replacement fluid and maintained for 48h, respectively until the crossover. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVVH with Biphozyl® in the first 48h after randomization
Description: After randomization into the Biphozyl®-group, CVVH will be initiated with Biphozyl® as a replacement fluid and maintained for 48h, respectively until the crossover. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVVH with Phoxilium® in the second 48h after randomization (after previous 48h with Biphozyl®)
Description: 48h post randomization, respectively after the cross-over CVVH will be continued with Phoxilium® for another 48h. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVVH with Biphozyl® in the second 48h after randomization (after previous 48h with Phoxilium®)
Description: 48h post randomization, respectively after the cross-over CVVH will be continued with Biphozyl® for another 48h. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
Study: NCT04390997

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non-surgical Periodontal Treatment
Description: Non-surgical periodontal treatment includes scaling and root planning by using curettes and ultrasonic devices only in the periodontitis group.